Bourgeon Capital Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Bourgeon Capital Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13,000	Closed	-$228K	–	301
2021 Q3	$228K	Sell	13,000 -27,250	-68%	-$318K	0.05%	102
2021 Q2	$390K	Buy	40,250 +10,000	+33%	+$94.1K	0.08%	91
2021 Q1	$325K	Buy	30,250 +7,000	+30%	+$86.6K	0.07%	96
2020 Q4	$342K	Buy	+23,250	New	+$335K	0.08%	84

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Bourgeon Capital Management's TRIL Position: Q4 2021 in Review

Bourgeon Capital Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 13,000 shares — an estimated $228K sold.

Bourgeon Capital Management first reported a position in TRIL in Q4 2020 and held it in 4 quarters. The position peaked at $390K in Q2 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Bourgeon Capital Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Bourgeon Capital Management sold 13,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $228K.
Bourgeon Capital Management first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 4 quarters.
Bourgeon Capital Management's Trillium Therapeutics Inc. position peaked at $390K in Q2 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Bourgeon Capital Management's 13F filing for Q4 2021, filed 31 Jan 2022.